Blade, Nice going with IOVA :o) Also, a nice move with CRDF, and JSPR is having a nice bounce. I'll check out the other picks, Thanks :o)
The only bio stock I've been following lately has been Acurx (ACXP). They have a new antibiotic approach for C. Dif infections, with a small Phase 2b completed, but very limited durability data available. Phase 3 is planned for later this year, but looks like the Phase 2b data may not be sufficient to get a decent partnership deal, which will mean dilution. So a typical biotech, with lots of promise but plenty of risk :o)
'Amtagvi / Lifileucel' ---> You have to wonder how they come up with these names lol. Probably an Ai program, but they are tongue twisters ..
---
News 
Market Data 
Discover 
